Technique for producing rivastigmine hydrogen tartrate
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- 苏州凯达生物医药技术有限公司
- Publication Date
- 2008-08-13
- Estimated Expiration
- Not applicable · inactive patent
Smart Images
Figure 1 Figure 2 Figure 3
Abstract
Description
technical field
[0001] The invention relates to a production process of rivastigmine bitartrate, in particular to a production process of anti-senile dementia drug rivastigmine bitartrate. Background technique
[0002] Rivastigmine bitartrate is a second-generation selective central, reversible, long-acting non-competitive acetylcholinesterase (AchE) and butyrylcholinesterase (BchE) inhibitor developed by Novartis. It can not only be used to treat mild and moderate Alzheimer's dementia, but also has a more significant effect on patients with advanced severe AD. However, the high production cost of rivastigmine bitartrate leads to high market price, so it is necessary to study its synthetic route, find a better synthetic method, reduce the cost and make it more suitable for domestic production. Contents of the invention
[0003] The purpose of the present invention is to provide a kind of production technology of rivastigmine hydrotartrate, and its operation is simple and ...